US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CytomX Therapeutics

2.70

+0.06502.47%

Post-market: 2.700.00000.00%16:01 EDT

Volume:2.55M

Turnover:6.95M

Market Cap:425.37M

PE:5.56

High:2.83

Open:2.63

Low:2.57

Close:2.64

Loading ...

Overview Company News Filings

CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

Neumora Stock Hits Record Low on Depression Drug Study Failure

PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

CytomX heading into ‘major catalyst year,’ says JonesResearch

JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723

Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek

AZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLC

VRTX Down as Non-Opioid Drug Shows Similar Pain Reduction as Placebo

KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707

SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder

GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer

EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study

Merck Ends Development of Two Experimental Cancer Drugs

CHMP Endorses Merck's Kidney Cancer Drug for Two Indications

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline

KRYS Stock Down on Initial Clinical Updates on KB407 & KB408

SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CTMX/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CTMX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTMX\",,,,,undefined,":{"symbol":"CTMX","market":"US","secType":"STK","nameCN":"CytomX Therapeutics","latestPrice":2.7,"timestamp":1749585600000,"preClose":2.635,"halted":0,"volume":2550477,"hourTrading":{"tag":"盘后","latestPrice":2.7,"preClose":2.7,"latestTime":"16:01 EDT","volume":2850,"amount":7695.000000000001,"timestamp":1749585679750},"delay":0,"floatShares":152000000,"shares":157544369,"eps":0.485379,"marketStatus":"Post-Mkt","change":0.065,"latestTime":"06-10 16:02:38 EDT","open":2.63,"high":2.825,"low":2.57,"amount":6950899.133841,"amplitude":0.096774,"askPrice":2.85,"askSize":400,"bidPrice":2.7,"bidSize":600,"shortable":3,"etf":0,"ttmEps":0.485379,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1749600000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1444276800000,"exchange":"NASDAQ","adjPreClose":2.635,"preHourTrading":{"tag":"盘前","latestPrice":2.65,"preClose":2.635,"latestTime":"09:28 EDT","volume":4737,"amount":12581.4871584,"timestamp":1749562080046},"postHourTrading":{"tag":"盘后","latestPrice":2.7,"preClose":2.7,"latestTime":"16:01 EDT","volume":2850,"amount":7695.000000000001,"timestamp":1749585679750},"volumeRatio":0.941728,"impliedVol":1.0469,"impliedVolPercentile":0.436},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTMX\",,,,,undefined,":{"symbol":"CTMX","floatShares":152000000,"roa":"15.87%","roe":"-139.27%","lyrEps":0.377419,"volumeRatio":0.941728,"shares":157544369,"dividePrice":0,"high":2.825,"amplitude":0.096774,"preClose":2.635,"low":2.57,"week52Low":0.4,"pbRate":"16.98","psRate":"2.88","week52High":2.875,"institutionHeld":0,"latestPrice":2.7,"committee":0.2,"eps":0.485379,"divideRate":0,"volume":2550477,"delay":0,"ttmEps":0.485379,"open":2.63,"prevYearClose":1.03,"prevWeekClose":2.64,"prevMonthClose":2.65,"prevQuarterClose":0.6358,"fiveDayClose":2.65,"twentyDayClose":2.13,"sixtyDayClose":0.6496},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTMX\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2500981141","title":"CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2500981141","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500981141?lang=en_us&edition=fundamental","pubTime":"2025-01-03 23:23","pubTimestamp":1735917780,"startTime":"0","endTime":"0","summary":"Shares of Capricor Therapeutics CAPR gained 8.4% on Thursday following the completion of the submission of a biologics license application  to the FDA seeking full approval for deramiocel to treat patients diagnosed with Duchenne muscular dystrophy  cardiomyopathy. CAPR’s lead product candidate and only clinical pipeline asset, deramiocel, is an investigational, allogeneic cardiac-derived cell therapy. A final decision of the FDA is anticipated in the second half of 2024.Capricor initiated its rolling submission process for the deramiocel BLA in October 2024, based on a successful pre-BLA meeting with the FDA. The completion of the submission process has also triggered a $10 million milestone payment from its distribution partner, Nippon Shinyaku, under the terms of the companies’ U.S. Commercialization and Distribution Agreement. The impending influx of cash is set to strengthen CAPR’s cash position.In the past three months, shares of Capricor have plunged 30.9% compared with the indu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/capr-stock-completion-rolling-submission-152300104.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSTL","CTMX","BK4196","BK4139","SPRO","CAPR"],"gpt_icon":0},{"id":"2500145917","title":"Neumora Stock Hits Record Low on Depression Drug Study Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2500145917","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500145917?lang=en_us&edition=fundamental","pubTime":"2025-01-03 22:14","pubTimestamp":1735913640,"startTime":"0","endTime":"0","summary":"The phase III KOASTAL-1 study evaluated the efficacy and safety of navacaprant against placebo in adults with moderate-to-severe MDD over a six-week treatment period. The study failed to achieve its primary endpoint – treatment with the drug failed to demonstrate a significant improvement over placebo in alleviating depression symptoms, as measured by the Montgomery-Asberg Depression Rating Scale .The study also failed to show statistically significant improvement in the reduction of anhedonia , as assessed by the Snaith-Hamilton Pleasure Scale .The KOASTAL-1 study is one of the three late-stage studies in the KOASTAL program evaluating navacaprant in the MDD indication. Despite the study's failure, Neumora intends to continue the other two studies. In the meantime, management continues to further analyze the study results, as management claimed that the drug showed an efficacy signal in female patients.Following the news, shares of Neumora hit an all-time low of $1.83. The latest anno","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neumora-stock-hits-record-low-141400263.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSTL","NMRA","SPRO","BK4196","CTMX","BK4139","BK4007","ABVC"],"gpt_icon":0},{"id":"2500902522","title":"PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?","url":"https://stock-news.laohu8.com/highlight/detail?id=2500902522","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500902522?lang=en_us&edition=fundamental","pubTime":"2025-01-03 02:28","pubTimestamp":1735842480,"startTime":"0","endTime":"0","summary":"Shares of Precigen PGEN have soared nearly 43% in the past week after the company provided an encouraging regulatory update for its lead pipeline program.Last week, Precigen announced that it has completed a rolling submission for a biologic license application  seeking the FDA’s accelerated approval for PRGN-2012, an experimental gene therapy to treat adults with recurrent respiratory papillomatosis .A rare disease, RRP causes benign tumors  to grow in the respiratory tract, most commonly in the larynx . It is caused by two types of human papilloma virus  – HPV 6 and HPV 11.The BLA is supported by data from a pivotal phase I/II study that evaluated PRGN-2012 for the treatment of adult patients with RRP. Data from the study showed that more than 50% of patients achieved a complete response . Also, more than 85% of patients experienced a reduction in surgical interventions in the year after receiving PRGN-2012 compared to the year before receiving the therapy.Precigen currently carries ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pgen-stock-surges-more-40-182800609.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","CSTL","BK4583","PGEN","CTMX","INO","BK4196","BK4139"],"gpt_icon":0},{"id":"2500007971","title":"VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag","url":"https://stock-news.laohu8.com/highlight/detail?id=2500007971","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500007971?lang=en_us&edition=fundamental","pubTime":"2025-01-02 22:56","pubTimestamp":1735829760,"startTime":"0","endTime":"0","summary":"Both avutometinib and defactinib have been in-licensed by Verastem from other pharmaceutical companies. Avutometinib is an RAF/MEK clamp, while defactinib is a best-in-class selective FAK inhibitor.In the past three months, shares of Verastem have surged 86.6% against the industry’s 9.5% decline.More on the FDA Acceptance of Avutometinib NDA for LGSOC. At present, there are no FDA-approved treatments specifically for LGSOC, a rare and distinct type of ovarian cancer with unique biology and treatment responses compared to high-grade serous ovarian cancer, representing a huge unmet medical need. Per Verastem, an estimated 6,000-8,000 women in theUnited Statesand 80,000 worldwide suffer from this disease. The standard of care treatment includes hormone therapy and chemotherapy.Currently, the company is enrolling patients with recurrent LGSOC regardless of KRAS mutation status in the global phase III RAMP 301 study, which is expected to serve as a confirmatory study for the initial indica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vstm-nda-ovarian-cancer-combo-145600394.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSTL","BK4139","CTMX","VSTM","SPRO","BK4196"],"gpt_icon":0},{"id":"2495540747","title":"CytomX heading into ‘major catalyst year,’ says JonesResearch","url":"https://stock-news.laohu8.com/highlight/detail?id=2495540747","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495540747?lang=en_us&edition=fundamental","pubTime":"2024-12-30 22:15","pubTimestamp":1735568125,"startTime":"0","endTime":"0","summary":"JonesResearch analyst Soumit Roy keeps a Buy rating on CytomX Therapeutics (CTMX) with a $7 price target after the company announced the new drug a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cytomx-heading-into-major-catalyst-year-says-jonesresearch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cytomx-heading-into-major-catalyst-year-says-jonesresearch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CTMX"],"gpt_icon":0},{"id":"2494385582","title":"JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723","url":"https://stock-news.laohu8.com/highlight/detail?id=2494385582","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494385582?lang=en_us&edition=fundamental","pubTime":"2024-12-27 20:17","pubTimestamp":1735301820,"startTime":"0","endTime":"0","summary":"How the Licensing Deal for the AD Program Benefits JNJ. The licensing deal with Kaken reinforces Johnson & Johnson’s dedication to targeting disease-specific pathways across diverse patient populations, leveraging innovative mechanisms and approaches to revolutionize the treatment of AD and other autoimmune and allergic conditions.Per JNJ, most AD patients fail to achieve remission with currently available treatments, representing a huge unmet medical need. The company believes that the STAT6 program stands out as a promising research area, offering the potential for a safe and effective novel oral therapy for those suffering from AD and other autoimmune diseases.In the past three months, shares of JNJ have lost 10.2% compared with the industry’s 13.8% decline.Some better-ranked stocks from the sector areCastle BiosciencesCSTL,CytomX TherapeuticsCTMX andSpero TherapeuticsSPRO, each sporting a Zacks Rank #1  at present. You can seethe complete list of today’s Zacks #1 Rank stocks here.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jnj-inks-licensing-deal-kaken-121700393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","LU1066051498.USD","IE00B4R5TH58.HKD","LU1066051811.HKD","LU1894683348.USD","IE00B3PB1722.GBP","LU0203347892.USD","BK4585","LU0058720904.USD","LU0289739699.SGD","LU1778281490.HKD","LU0122379950.USD","BK4550","LU0345770993.USD","LU0912757837.SGD","LU1221951129.SGD","IE00BGHQF631.EUR","LU1057294990.SGD","LU1674673428.USD","LU1244550494.USD","LU0889566641.SGD","CSTL","SG9999002224.SGD","LU0795875169.SGD","SPRO","CTMX","LU1914381329.SGD","LU1196500208.SGD","IE00BDGV0183.EUR","LU1066051225.USD","LU1221951046.USD","LU1674673691.USD","BK4532","BK4588","LU1732799900.SGD","IE0009355771.USD","IE00BJT1NW94.SGD","LU0098860793.USD","LU0234570918.USD","IE00BSNM7G36.USD","BK4581","LU0466842654.USD","IE000M9KFDE8.USD","LU1032466523.USD","BK4568","LU0203345920.USD","BK4139","JNJ","LU1261432733.SGD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2493797799","title":"Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek","url":"https://stock-news.laohu8.com/highlight/detail?id=2493797799","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493797799?lang=en_us&edition=fundamental","pubTime":"2024-12-24 02:44","pubTimestamp":1734979440,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals VRTX announced that the FDA has approved its next-in-class vanza triple therapy for treating people with cystic fibrosis  aged six years and above. The drug will be marketed under the brand name Alyftrek.Post the FDA’s approval, the orally administered Alyftrek has been approved for use in CF patients aged six years and older who have at least one F508del mutation or another responsive mutation in the CF transmembrane conductance regulator  gene responsive to the drug. The drug will be available at a wholesale acquisition cost of $370,269 on an annual basis.The FDA’s decision came earlier than the expected PDUFA date of Jan 2, 2025. The approval is based on data from a comprehensive late-stage program, which showed that treatment with once-daily Alyftrek enhanced patient benefit compared to Vertex’s blockbuster CF drug Trikafta , which is required to be administered twice daily. The drug is also eligible for use in CF patients who have discontinued Trikafta or Ve","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UgiI07ytew_hNcL7MgLFiA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5c26ab1f8b890434759145296588998c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UgiI07ytew_hNcL7MgLFiA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5c26ab1f8b890434759145296588998c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vertex-secures-fda-approval-cystic-184400620.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4023","BK4533","CSTL","VTNR","VERX","LU0889565916.HKD","IE00BFTCPJ56.SGD","VRTX","LU0058720904.USD","BK4138","LU2362541513.USD","CTMX","LU0061475181.USD","BK4532","MRNA","LU0234570918.USD","BK4196","LU1585245621.USD","IE00BZ9MQY76.HKD","LU0320765992.SGD","LU0109394709.USD","BK4534","LU0417517546.SGD","LU1093756168.USD","LU2237438978.USD","BK4551","IE0002141913.USD","IE00B19Z3581.USD","LU0256863811.USD","LU1093756325.SGD","BK4585","LU0079474960.USD","IE00B19Z3B42.SGD","IE00B19Z9P08.USD","LU2417539215.USD","BK4567","CF","LU2362541273.HKD","LU1069344957.HKD","LU1430594728.SGD","LU2456880835.USD","IE00B2B36J28.USD","BK4588","IE00B4R5TH58.HKD","LU0566484027.USD","BK4093","BK4501","BK4139","BK4548","LU2236285917.USD"],"gpt_icon":0},{"id":"2493934307","title":"AZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2493934307","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493934307?lang=en_us&edition=fundamental","pubTime":"2024-12-23 23:56","pubTimestamp":1734969360,"startTime":"0","endTime":"0","summary":"AstraZenecaAZN announced that its blockbuster cancer drug, Tagrisso , has been approved in the EU for expanded use in non-small cell lung cancer .The eligible patient population includes adults with locally advanced, unresectable NSCLC with EGFR exon 19 deletions  or exon 21  substitution mutations whose disease has not progressed during or following platinum-based chemoradiation therapy. The FDAapprovedthis combinationin September for a similar indication.The nod in the EU is based on data from the phase III LAURAstudy, which showed that treatment with Tagrisso reduced the risk of disease progression or death by 84% compared to placebo. Patients treated with the drug experienced a median progression-free survival of 39.1 months compared with 5.6 months for patients in the placebo group. The drugs’ safety and tolerability profiles were consistent with prior studies and no new safety concerns were identified.Last month, the EMA’s advisory committee adopted a positive opinion, recommendi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/spvq99_pwlnf7s60ZXBlKg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/06708d71c63051ca48bf1855727f077b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/spvq99_pwlnf7s60ZXBlKg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/06708d71c63051ca48bf1855727f077b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/azns-tagrisso-gets-approval-eu-155600638.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AZN","BK4139","LU2462157665.USD","CTMX","LU2236285917.USD","BK4585","SPRO","BK4588","BK4156","LU0320765992.SGD","LU2417539215.USD","LU1829250122.USD","LU0109394709.USD","BK4196","LU2456880835.USD","BK4568","CSTL","LU0889565916.HKD","BK4007"],"gpt_icon":0},{"id":"2493424389","title":"VRTX Down as Non-Opioid Drug Shows Similar Pain Reduction as Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2493424389","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493424389?lang=en_us&edition=fundamental","pubTime":"2024-12-21 00:13","pubTimestamp":1734711180,"startTime":"0","endTime":"0","summary":"Shares of Vertex Pharmaceuticals Incorporated VRTX were down 11.4% yesterday after the company announced data from a phase II study that evaluated its investigational, oral, highly selective NaV1.8 pain signal inhibitor, suzetrigine, for treating people with painful lumbosacral radiculopathy , a form of peripheral neuropathic pain.Data from the study showed that treatment with suzetrigine led to a statistically significant and clinically meaningful within-group reduction in pain from baseline with a mean change in numeric pain rating scale of -2.02 at week 12, thereby meeting the primary endpoint.However, the placebo arm demonstrated a similar reduction of -1.98 points, indicating not much difference between the two groups.Shares of VRTX were down as investors were not too impressed with the data as it does not clearly demonstrate suzetrigine’s benefit-risk profile.Year to date, shares of Vertex have lost 2.5% compared with the industry’s decline of 13.7%.However, the disappointing dat","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vrtx-down-non-opioid-drug-161300244.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0058720904.USD","BK4023","LU2456880835.USD","IE00B2B36J28.USD","LU0320765992.SGD","LU0823416689.USD","BK4585","LU1585245621.USD","LU0109394709.USD","BK4533","LU2362541273.HKD","IE0009355771.USD","LU0061475181.USD","LU0256863811.USD","LU0889565916.HKD","LU1035775433.USD","LU2417539215.USD","IE00B4R5TH58.HKD","LU1430594728.SGD","CTMX","IE00BFTCPJ56.SGD","LU1093756325.SGD","CSTL","VRTX","LU1093756168.USD","LU2237438978.USD","LU2462157665.USD","IE0002270589.USD","IE00BJT1NW94.SGD","BK4567","IE00B19Z3581.USD","SPRO","BK4532","LU0079474960.USD","LU1069344957.HKD","LU2362541513.USD","LU2362540622.SGD","BK4588","IE00B894F039.SGD","LU2236285917.USD","LU2324357040.USD","IE00B19Z9P08.USD","IE00B19Z3B42.SGD","IE00B19Z9Z06.USD","IE00BJJMRZ35.SGD","LU1559883803.SGD","VERX","IE00BZ9MQY76.HKD","LU0566484027.USD","LU0234570918.USD"],"gpt_icon":0},{"id":"2492025121","title":"KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707","url":"https://stock-news.laohu8.com/highlight/detail?id=2492025121","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492025121?lang=en_us&edition=fundamental","pubTime":"2024-12-20 00:08","pubTimestamp":1734624480,"startTime":"0","endTime":"0","summary":"Krystal BiotechKRYS announced encouraging initial clinical data from an early to mid-stage study of its investigational immunotherapy candidate, KB707, to treat patients with solid tumors of the lung.The phase I/II KYANITE-1 study is evaluating the safety, tolerability and tumor response  of inhaled KB707 as a monotherapy in 37 patients with malignant lesions in the lung. Out of the total enrolled patient population, 17 were diagnosed with advanced non-small cell lung cancer . Two doses of KB707  were evaluated during the dose-escalation phase of the KYANITE-1 study, following which 109PFU was selected for dose expansion.Results showed that patients treated with inhaled KB707 demonstrated early evidence of monotherapy activity with the most therapeutic benefit observed in advanced NSCLC patients, who have progressed after standard-of-care treatments.In the past three months, shares of Krystal Biotech have lost 14.9% compared with theindustry’s 13.3% decline.KB707 is also being develope","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2NHx6klCutBjAlMNJEM7HQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b5aeac1c53d022d48463312844fb1baf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2NHx6klCutBjAlMNJEM7HQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b5aeac1c53d022d48463312844fb1baf"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/krys-reports-upbeat-initial-data-160800963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","SPRO","CSTL","KRYS","CTMX","BK4139"],"gpt_icon":0},{"id":"2492174258","title":"SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2492174258","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492174258?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:45","pubTimestamp":1734615900,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics SRPT announced that it has completed enrolment and dosing in the phase III EMERGENE study evaluating its investigational gene therapy, SRP-9003  for treating limb-girdle muscular dystrophy  Type 2E/R4 .Data from the EMERGENE study is expected in the first half of 2025. If the data is positive, Sarepta intends to submit a regulatory filing seeking accelerated approval for SRP-9003 in the given indication before the end of next year.The primary endpoint of the study is the biomarker expression of the beta-sarcoglycan protein, whose absence is the sole cause of the disease.LGMD2E/R4 is an ultra-rare form of LGMD for which there is no treatment beyond symptom management. Patients suffering from this genetic disease exhibit neuromuscular symptoms, which include difficulty in running, jumping and climbing stairs, before the age of 10. Because of the lack of treatments, the disease often progresses to loss of mobility during the teenage years and is associated with early ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2ZuhDuDie_37lq4aVERX2Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4718122d03716403704541c667907c4e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2ZuhDuDie_37lq4aVERX2Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4718122d03716403704541c667907c4e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/srpt-finishes-enrolment-stage-study-134500600.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","BK4139","IE00BJT1NW94.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","BK4007","SSI","RHHBY","BK4585","CTMX","IE0009355771.USD","IE00BJJMRZ35.SGD","SRPT","IE00B2B36J28.USD","03165","CSTL"],"gpt_icon":0},{"id":"2492135482","title":"GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2492135482","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492135482?lang=en_us&edition=fundamental","pubTime":"2024-12-18 23:14","pubTimestamp":1734534840,"startTime":"0","endTime":"0","summary":"Gilead SciencesGILD announced that its first-in-class Trop-2-directed antibody-drug conjugate, Trodelvy, has been granted a second Breakthrough Therapy designationby the FDA for a lung cancer indication. The indicated population includes adult patients with extensive-stage small cell lung cancer  whose disease has progressed on or after platinum-based chemotherapy.Gilead’s Trodelvy is currently approved for second-line or later metastatic triple-negative breast cancer  patients in more than 50 countries and for certain patients with pre-treated HR+/HER2- metastatic breast cancer  in more than 40 countries, including the United States. The first Breakthrough Therapy designation was granted to Trodelvy for the TNBC indication in the United States.Benefits of the FDA’s Breakthrough Therapy Designation Grant. The FDA’s Breakthrough Therapy designation is a process that speeds up the development and review of drugs for serious or life-threatening conditions. This designation is granted when","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2Uxrul9Xalj9HwUZqlOfZA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2Uxrul9Xalj9HwUZqlOfZA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilds-trodelvy-gets-second-breakthrough-151400252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRO","BK4568","LU1430594728.SGD","BK4139","LU0320765992.SGD","GILD","LU1839511570.USD","LU0234570918.USD","LU0289739699.SGD","LU0889565916.HKD","BK4566","IE0002270589.USD","IE00BZ1G4Q59.USD","BK4532","IE00B3T34201.USD","CTMX","LU0109394709.USD","LU0058720904.USD","BK4086","IE00BSNM7G36.USD","BK4583","IE00B19Z3B42.SGD","LU1571399168.USD","CSTL","LU1585245621.USD","IE00BKVL7J92.USD","BK4588","BK4585","LU1066053197.SGD","BK4550","LU2468319806.SGD","LU1066051498.USD","IE00B19Z3581.USD","IE00B7SZLL34.SGD","BK4196","BK4578","LU2087621335.USD","MBC"],"gpt_icon":0},{"id":"2492961333","title":"EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2492961333","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492961333?lang=en_us&edition=fundamental","pubTime":"2024-12-17 22:18","pubTimestamp":1734445080,"startTime":"0","endTime":"0","summary":"Shares of Edgewise Therapeutics EWTX were up more than 18% on Monday after it announced positive results from the mid-stage CANYON study on its lead pipeline drug, sevasemten, in patients with a rare genetic disorder called Becker Muscular Dystrophy .The study met its primary endpoint of change from baseline in creatine kinase , a biomarker associated with skeletal muscle damage. Data from the study showed a significant reduction in CK levels in the sevasemten-treated group, with an average decrease of 28% compared to placebo between six and 12 months. The drug was also well-tolerated by study participants.Edgewise remains on schedule to complete recruitment for a pivotal cohort of the CANYON study, called GRAND CANYON, which is expected to be achieved in the first quarter of 2025. If data from this cohort is also positive, management intends to start discussions with the FDA and EMA for seeking approval for sevasemten in the BMD indication.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ewtx-stock-rises-upbeat-data-141800266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSTL","BK4588","BK4531","BK4007","CTMX","SPRO","BK4585","BK4539","EWTX","BK4139","BK4196","HCM"],"gpt_icon":0},{"id":"2492962747","title":"Merck Ends Development of Two Experimental Cancer Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2492962747","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492962747?lang=en_us&edition=fundamental","pubTime":"2024-12-17 22:03","pubTimestamp":1734444180,"startTime":"0","endTime":"0","summary":"Merck MRK decided to discontinue two clinical development programs, namely KeyVibe and KEYFORM, which are evaluating its investigational cancer drugs vibostolimab and favezelimab, respectively.Merck’s decision followed a series of setbacks for both drugs, which were being tested in combination with its blockbuster drug Keytruda for various cancer indications across multiple late-stage studies. After a detailed review of data from the clinical studies on both drugs, management has decided to focus on its other ongoing pipeline programs.Merck’s decision to discontinue development on vibostolimab is based on a pre-planned analysis of data from the two phase III studies, KeyVibe-003 and KeyVibe-007, conducted by an independent data monitoring committee . These studies evaluated the combination of vibostolimab and Keytruda in certain patients with non-small cell lung cancer  compared to Keytruda alone.Keytruda sales benefited from rapid uptake across earlier-stage indications in triple-nega","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1YvkxNLsEvDesNn9Nqp_Qw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/df847a6f57145ec8b42be7c65f980057","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1YvkxNLsEvDesNn9Nqp_Qw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/df847a6f57145ec8b42be7c65f980057"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/merck-ends-development-two-experimental-140300151.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4533","CSTL","LU1023059063.AUD","LU1093756168.USD","SG9999014542.SGD","CTMX","LU0208291251.USD","IE00BJT1NW94.SGD","LU0289739699.SGD","LU1430594728.SGD","SPRO","IE00BJJMRZ35.SGD","IE00BBT3K403.USD","SGXZ57979304.SGD","LU1037948541.HKD","LU1066053197.SGD","SG9999014559.SGD","LU0106261372.USD","IE00BLSP4452.SGD","LU1116320901.HKD","IE0002141913.USD","LU1037948897.HKD","BK4550","LU0861579265.USD","LU1989772840.SGD","LU1093756325.SGD","SG9999002232.USD","LU1066051811.HKD","LU0070302665.USD","LU0266013472.USD","LU1291159041.SGD","LU1974910355.USD","BK4196","IE00BN8TJ469.HKD","LU1066051225.USD","LU1983299246.USD","LU2023250843.SGD","LU2361044865.SGD","IE0009355771.USD","MRK","SG9999002224.SGD","BK4585","SG9999001176.USD","LU1989772923.USD","BK4534","LU1571399168.USD","BK4559","IE00BFTCPJ56.SGD","LU0965509010.AUD","LU0006306889.USD"],"gpt_icon":0},{"id":"2492661245","title":"CHMP Endorses Merck's Kidney Cancer Drug for Two Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2492661245","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492661245?lang=en_us&edition=fundamental","pubTime":"2024-12-16 23:57","pubTimestamp":1734364620,"startTime":"0","endTime":"0","summary":"Merck MRK announced that EMA’s Committee for Medicinal Products for Human Use  recommended granting conditional approval to its oral HIF-2α inhibitor, Welireg , for use in two indications associated with renal cell carcinoma .The CHMP recommended Welireg to treat adult patients with von Hippel-Lindau  disease who require therapy for associated RCC, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors, not requiring immediate surgery. This committee also endorsed the drug for a second indication to treat adult patients with advanced RCC who have received at least two lines of therapy, which include anti-PD-1 and VEGF-targeted therapies.A final decision from the European Commission on both indications is expected in the first quarter of 2025. If approved, Welireg will be the first systemic treatment for patients with VHL disease-associated tumors in the European Union.The LITESPARK-004 study achieved its major efficacy endpoint, treatment with Welireg achieved an ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1YvkxNLsEvDesNn9Nqp_Qw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/df847a6f57145ec8b42be7c65f980057","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1YvkxNLsEvDesNn9Nqp_Qw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/df847a6f57145ec8b42be7c65f980057"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chmp-endorses-mercks-kidney-cancer-155700240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MRK","LU0122379950.USD","LU2106854487.HKD","IE00BBT3K403.USD","IE00B4R5TH58.HKD","LU1066053197.SGD","LU0965508806.USD","LU0058720904.USD","LU1989772840.SGD","LU0965509283.SGD","SG9999015358.SGD","LU0965509010.AUD","SG9999015341.SGD","BK4559","BK4007","BK4585","LU2023250504.SGD","LU0265550359.USD","LU0861579265.USD","SG9999001440.SGD","LU1430594728.SGD","SG9999001176.SGD","IE00BLSP4452.SGD","IE00B1BXHZ80.USD","IE00BJT1NW94.SGD","SG9999013999.USD","SG9999014567.USD","CTMX","LU0211331839.USD","LU0266013472.USD","IE0009355771.USD","LU2361044865.SGD","LU2468319806.SGD","LU1037948897.HKD","IE00BSNM7G36.USD","IE00BFTCPJ56.SGD","CSTL","LU1291159041.SGD","LU1983299246.USD","LU1699723380.USD","LU1941712348.USD","SPRO","LU0106261372.USD","LU1571399168.USD","LU1934455194.USD","LU1057294990.SGD","LU1066051498.USD","BK4139","LU1917777945.USD","CHMP"],"gpt_icon":0},{"id":"2492612453","title":"EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce","url":"https://stock-news.laohu8.com/highlight/detail?id=2492612453","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492612453?lang=en_us&edition=fundamental","pubTime":"2024-12-16 23:43","pubTimestamp":1734363780,"startTime":"0","endTime":"0","summary":"Shares of Editas Medicine EDIT plunged 23.8% on Dec. 13 after it announced a strategic decision to end the development of its lead gene editing therapy, reni-cel, following the failure of an extensive search to yield a commercial partner. The company is already facing a massive cash crunch and without a partner, it is unable to sustain the development cost of reni-cel. The candidate was evaluated in a phase I/II/III RUBY study and a phase I/II EdiTHAL study for severe sickle cell disease  and transfusion-dependent beta thalassemia , respectively.Per Editas, it plans to work closely with the clinical study sites, regulators and other parties to determine the path forward for patients enrolled in the RUBY and EdiTHAL studies. The abandonment of these studies has significantly delayed the company’s hopes of earning any revenues.Additionally, the biology of HBG1/2 has been validated in clinical settings, such as the RUBY study with reni-cel, further supporting its potential. Beyond HSCs, E","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/edit-stock-falls-decision-end-154300702.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4556","CSTL","EDIT","CTMX","BK4196","SCD","BK4139","SPRO"],"gpt_icon":0},{"id":"2492612459","title":"CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2492612459","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492612459?lang=en_us&edition=fundamental","pubTime":"2024-12-16 22:55","pubTimestamp":1734360907,"startTime":"0","endTime":"0","summary":"The price trend for CytomX Therapeutics  has been bearish lately and the stock has lost 5.9% over the past week. However, the formation of a hammer chart pattern in its last trading session indicates that the stock could witness a trend reversal soon, as bulls might have gained significant control over the price to help it find support.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for the stock. On the fundamental side, strong agreement among Wall Street analysts in raising earnings estimates for this biopharmaceutical company enhances its prospects of a trend reversal.What is a Hammer Chart and How to Trade It?If this is not enough, you should note that CTMX currently has a Zacks Rank #1 , which means it is in the top 5% of more than the 4,000 stocks that we rank","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/auhFPLcthJM50UYepXcODg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2f0d6efdd8740952a371c97ddea6e926","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/auhFPLcthJM50UYepXcODg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2f0d6efdd8740952a371c97ddea6e926"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cytomx-therapeutics-ctmx-may-bottom-145507919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTMX","BK4139"],"gpt_icon":0},{"id":"2492961989","title":"ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2492961989","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492961989?lang=en_us&edition=fundamental","pubTime":"2024-12-16 22:42","pubTimestamp":1734360120,"startTime":"0","endTime":"0","summary":"AbbVieABBV announced that it has entered into a definitive agreement to acquire privately held biotech, Nimble Therapeutics. The impending acquisition will add Nimble’s lead preclinical asset and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases to AbbiVie’s Immunology pipeline. The acquisition also allows AbbVie to utilize Nimble's proprietary peptide synthesis platform to enable the discovery and optimization of oral peptide therapeutics.Nimble’s lead preclinical asset is an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis and inflammatory bowel disease . Per AbbVie, IL23R is a validated therapeutic target in certain autoimmune diseases, significantly contributing to psoriasis and IBD by driving inflammation and enhancing immune responses.In the past three months, shares of AbbVie have lost 10.4% compared with the industry’s 14.4% decline.Skyrizi and Rinvoq are expected to collecti","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/D3ML88PGy1H5kHT9yl7OAw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/D3ML88PGy1H5kHT9yl7OAw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbv-acquire-nimble-therapeutics-strengthen-144200195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1551013342.USD","LU1839511570.USD","LU0661504455.SGD","LU1244550494.USD","LU0912757837.SGD","SPRO","LU1291159041.SGD","LU0965509101.SGD","LU0122379950.USD","IE00BDGV0183.EUR","LU0738911758.USD","LU2237443978.SGD","CSTL","LU0203347892.USD","LU1037948541.HKD","CTMX","LU0256863811.USD","IE00B42XCP33.USD","IE00BSNM7G36.USD","SG9999011175.SGD","SG9999015978.USD","IE0009355771.USD","IE00BVYPNV92.GBP","LU2237443382.USD","LENZ","ABBV","BK4588","LU0795875086.SGD","LU0158827948.USD","LU0965509283.SGD","LU0820561818.USD","LU1267930573.SGD","LU0689472784.USD","BK4566","LU2089284900.SGD","LU1057294990.SGD","BK4196","LU2237443549.SGD","LU0256863902.USD","LU1718418525.SGD","LU2237443622.USD","LU2089283258.USD","LU0456855351.SGD","LU1496350171.SGD","IE0004445239.USD","LU1061106388.HKD","IBD","LU2023251221.USD","LU0170899867.USD","LU0882574055.USD"],"gpt_icon":0},{"id":"2491930999","title":"KRYS Stock Down on Initial Clinical Updates on KB407 & KB408","url":"https://stock-news.laohu8.com/highlight/detail?id=2491930999","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491930999?lang=en_us&edition=fundamental","pubTime":"2024-12-14 00:08","pubTimestamp":1734106080,"startTime":"0","endTime":"0","summary":"Krystal Biotech, Inc. KRYS announced initial clinical data updates on its two inhaled genetic medicine pipeline candidates, KB407 and KB408, which are being developed in early-stage studies for treating rare respiratory diseases.Shares of the company were down 7.3% on Dec. 12 following the announcement of the news.KB407 is being developed in a phase I study for the treatment of cystic fibrosis , while KB408 is being developed in a phase I study for treating alpha-1 antitrypsin deficiency .The latest clinical updates include molecular data as well as safety and tolerability data for both KB407 and KB408.Year to date, shares of Krystal Biotech have rallied 39.8% against the industry’s decline of 8.7%.The open-label, phase I CORAL-1 study is evaluating KB407 for treating adult patients with CF. The company recently activated two additional clinical sites for its KB407 phase I CORAL-1 study.Per the company, the CORAL-1 study is designed to include up to three dose escalation cohorts evalua","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/krys-stock-down-initial-clinical-160800239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CF","CTMX","BK4588","BK4093","CSTL","KRYS","BK4196","SPRO","BK4139","BK4585"],"gpt_icon":0},{"id":"2491305286","title":"SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS","url":"https://stock-news.laohu8.com/highlight/detail?id=2491305286","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491305286?lang=en_us&edition=fundamental","pubTime":"2024-12-13 23:58","pubTimestamp":1734105480,"startTime":"0","endTime":"0","summary":"Sanofi SNY announced that the FDA has granted a Breakthrough Therapy designation to its investigational oral BTK inhibitor, tolebrutinib, for treating adults with non-relapsing secondary progressive multiple sclerosis .The FDA grants breakthrough therapy designation to expedite the development and review of therapies for severe or life-threatening diseases where preliminary clinical evidence shows that the therapy may provide substantial improvements over available treatments.There are no approved therapies to treat nrSPMS at present. Multiple sclerosis  is a chronic neurodegenerative disease that causes disability accumulation over time, which is not properly addressed by the currently available therapies, and there remains a significant unmet need for MS treatment.Year to date, shares of Sanofi have declined 5.5% against the industry’s increase of 7.4%.Breakthrough Therapy Tag Based on Data From SNY's HERCULES Study. The FDA’s Breakthrough Therapy designation for tolebrutinib was bas","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/MPLv._QOfr9ekgf5qyZbUA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4c89fa4c828d913dc49739912177a966","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/MPLv._QOfr9ekgf5qyZbUA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4c89fa4c828d913dc49739912177a966"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/snys-tolebrutinib-gets-fda-breakthrough-155800256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0106831901.USD","LU1720051108.HKD","BK4223","LU1548497426.USD","BK4516","LU1989772840.SGD","LU2111349929.HKD","LU2357305700.SGD","LU0006306889.USD","LU0158827948.USD","LU1989772923.USD","BK4127","LU0971096721.USD","BK4007","BK4139","BK4581","IE00BKVL7J92.USD","BK4504","BK4123","IE00BFXG1179.USD","CDP","LU2028103732.USD","BK4585","LU0098860793.USD","LU0158827781.USD","LU2271345857.HKD","CSTL","LU0225283273.USD","IE0031619046.USD","LU2089284900.SGD","CTMX","LU1720051017.SGD","IE00B66KJ199.SGD","LU0106261372.USD","LU1074936037.SGD","IE00B7SZL793.SGD","LU1363072403.SGD","LU1162221912.USD","MG","LU0267386448.USD","LU0320765646.SGD","SNY","BK4534","BK4588","IE00BZ1G4Q59.USD","LU0314104364.USD","BK4196","SPRO","IE00B19Z4B17.USD","LU2089283258.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":6,"totalSize":122,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTMX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-12","symbol":"CTMX","fiscalQuarterEnding":"2025/03","expectedEps":0.18,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":0.27},{"market":"US","date":"2025-03-06","symbol":"CTMX","fiscalQuarterEnding":"2024/12","expectedEps":-0.2,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741237200000,"reportTimeType":"post","actualEps":0.22},{"market":"US","date":"2024-11-07","symbol":"CTMX","fiscalQuarterEnding":"2024/09","expectedEps":-0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2024-08-08","symbol":"CTMX","fiscalQuarterEnding":"2024/06","expectedEps":-0.07,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723089600000,"reportTimeType":"post","actualEps":-0.08},{"market":"US","date":"2024-05-08","symbol":"CTMX","fiscalQuarterEnding":"2024/03","expectedEps":-0.06,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"post","actualEps":0.17}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTMX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTMX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.3333,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":6,"updateTime":1747540800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CTMX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CTMX","date":"2025-06-09","current":9.997287,"percent":0.997545,"low":-610.657204,"twenty":-6.623429,"median":-1.975939,"eighty":1.474065,"high":17.165432,"avg":-11.604518,"sd":52.588144,"marketCap":415917134},"quantilePoints":[{"date":"2020-06-12","current":-4.815618,"twenty":-20.712849,"median":-14.355987,"eighty":-5.538565,"marketCap":365548711},{"date":"2020-06-19","current":-4.991061,"twenty":-20.67726,"median":-14.320237,"eighty":-5.498237,"marketCap":378866441},{"date":"2020-06-26","current":-4.960812,"twenty":-20.659465,"median":-14.307541,"eighty":-5.450843,"marketCap":376570281},{"date":"2020-07-02","current":-5.087857,"twenty":-20.576155,"median":-14.261373,"eighty":-5.410082,"marketCap":386214154},{"date":"2020-07-10","current":-5.15743,"twenty":-20.54514,"median":-14.219636,"eighty":-5.323504,"marketCap":391495322},{"date":"2020-07-17","current":-5.217927,"twenty":-20.527127,"median":-14.149251,"eighty":-5.258418,"marketCap":396087643},{"date":"2020-07-24","current":-4.694622,"twenty":-20.508161,"median":-14.129808,"eighty":-5.184654,"marketCap":356364070},{"date":"2020-07-31","current":-4.240889,"twenty":-20.453444,"median":-14.109343,"eighty":-5.169529,"marketCap":321921667},{"date":"2020-08-07","current":-5.620336,"twenty":-20.373286,"median":-14.106574,"eighty":-5.154405,"marketCap":351984762},{"date":"2020-08-14","current":-5.063465,"twenty":-20.352356,"median":-14.089783,"eighty":-5.154405,"marketCap":317109631},{"date":"2020-08-21","current":-5.126159,"twenty":-20.331137,"median":-14.019604,"eighty":-5.154405,"marketCap":321035970},{"date":"2020-08-28","current":-5.266299,"twenty":-20.312283,"median":-14.008481,"eighty":-5.154405,"marketCap":329812493},{"date":"2020-09-04","current":-4.838504,"twenty":-20.247683,"median":-13.96477,"eighty":-5.153195,"marketCap":303021002},{"date":"2020-09-11","current":-4.963892,"twenty":-20.22172,"median":-13.958967,"eighty":-5.109636,"marketCap":310873680},{"date":"2020-09-18","current":-5.458069,"twenty":-20.170596,"median":-13.951802,"eighty":-5.125358,"marketCap":341822472},{"date":"2020-09-25","current":-5.015523,"twenty":-20.11461,"median":-13.913989,"eighty":-5.067288,"marketCap":314107136},{"date":"2020-10-02","current":-4.772122,"twenty":-20.08008,"median":-13.899365,"eighty":-5.057355,"marketCap":298863702},{"date":"2020-10-09","current":-5.026586,"twenty":-20.064176,"median":-13.876559,"eighty":-5.053194,"marketCap":314800020},{"date":"2020-10-16","current":-5.059777,"twenty":-20.057081,"median":-13.857118,"eighty":-5.052064,"marketCap":316878670},{"date":"2020-10-23","current":-4.98602,"twenty":-20.043774,"median":-13.828188,"eighty":-5.029108,"marketCap":312259447},{"date":"2020-10-30","current":-4.882759,"twenty":-20.036656,"median":-13.801088,"eighty":-5.021444,"marketCap":305792536},{"date":"2020-11-06","current":-6.049502,"twenty":-20.01928,"median":-13.780006,"eighty":-5.018995,"marketCap":324495302},{"date":"2020-11-13","current":-6.376968,"twenty":-20.003719,"median":-13.762466,"eighty":-5.021444,"marketCap":342060574},{"date":"2020-11-20","current":-6.308028,"twenty":-19.990391,"median":-13.711175,"eighty":-5.022352,"marketCap":338362622},{"date":"2020-11-27","current":-6.394203,"twenty":-19.977759,"median":-13.596608,"eighty":-5.024373,"marketCap":342985062},{"date":"2020-12-04","current":-6.376968,"twenty":-19.969125,"median":-13.573758,"eighty":-5.026896,"marketCap":342060574},{"date":"2020-12-11","current":-6.532084,"twenty":-19.953786,"median":-13.48235,"eighty":-5.028526,"marketCap":350380967},{"date":"2020-12-18","current":-6.738904,"twenty":-19.927699,"median":-13.396874,"eighty":-5.032258,"marketCap":361474823},{"date":"2020-12-24","current":-6.394203,"twenty":-19.920158,"median":-13.309968,"eighty":-5.03608,"marketCap":342985062},{"date":"2020-12-31","current":-5.644479,"twenty":-19.913392,"median":-13.266804,"eighty":-5.039459,"marketCap":302769833},{"date":"2021-01-08","current":-6.376968,"twenty":-19.876131,"median":-13.133036,"eighty":-5.051559,"marketCap":342060574},{"date":"2021-01-15","current":-6.833697,"twenty":-19.875411,"median":-13.071715,"eighty":-5.052401,"marketCap":366559507},{"date":"2021-01-22","current":-7.50172,"twenty":-19.86922,"median":-13.049885,"eighty":-5.052401,"marketCap":402392271},{"date":"2021-01-29","current":-7.795021,"twenty":-19.846267,"median":-13.019446,"eighty":-5.053459,"marketCap":418124901},{"date":"2021-02-05","current":-9.390938,"twenty":-19.831701,"median":-12.942812,"eighty":-5.058566,"marketCap":503729902},{"date":"2021-02-12","current":-10.512244,"twenty":-19.824377,"median":-12.897211,"eighty":-5.059777,"marketCap":563876757},{"date":"2021-02-19","current":-10.418802,"twenty":-19.821989,"median":-12.77593,"eighty":-5.06199,"marketCap":558864519},{"date":"2021-02-26","current":-15.976239,"twenty":-19.809797,"median":-12.810718,"eighty":-5.063581,"marketCap":525378614},{"date":"2021-03-05","current":-15.833776,"twenty":-19.799678,"median":-12.921607,"eighty":-5.067288,"marketCap":520693709},{"date":"2021-03-12","current":-17.299112,"twenty":-19.76851,"median":-12.921607,"eighty":-5.067288,"marketCap":568881302},{"date":"2021-03-19","current":-16.831018,"twenty":-19.712796,"median":-12.921607,"eighty":-5.067288,"marketCap":553488043},{"date":"2021-03-26","current":-15.508145,"twenty":-19.620977,"median":-12.922693,"eighty":-5.068498,"marketCap":509985355},{"date":"2021-04-01","current":-16.016943,"twenty":-19.574255,"median":-12.922693,"eighty":-5.068498,"marketCap":526717158},{"date":"2021-04-09","current":-15.711664,"twenty":-19.474349,"median":-12.921607,"eighty":-5.067288,"marketCap":516678076},{"date":"2021-04-16","current":-15.284274,"twenty":-19.423718,"median":-12.921607,"eighty":-5.067288,"marketCap":502623362},{"date":"2021-04-23","current":-18.642337,"twenty":-19.348547,"median":-12.921607,"eighty":-5.067288,"marketCap":613053261},{"date":"2021-04-30","current":-18.502039,"twenty":-19.318728,"median":-12.921607,"eighty":-5.067288,"marketCap":608439564},{"date":"2021-05-07","current":-9.165707,"twenty":-19.246205,"median":-12.845506,"eighty":-5.067288,"marketCap":555845161},{"date":"2021-05-14","current":-8.747623,"twenty":-19.199134,"median":-12.654171,"eighty":-5.067288,"marketCap":530490820},{"date":"2021-05-21","current":-9.015626,"twenty":-19.199134,"median":-12.54111,"eighty":-5.067288,"marketCap":546743603},{"date":"2021-05-28","current":-7.67561,"twenty":-19.19054,"median":-12.410655,"eighty":-5.067288,"marketCap":465479690},{"date":"2021-06-04","current":-7.257525,"twenty":-19.109305,"median":-12.334551,"eighty":-5.067288,"marketCap":440125350},{"date":"2021-06-11","current":-7.67561,"twenty":-19.109305,"median":-12.217538,"eighty":-5.067288,"marketCap":465479690},{"date":"2021-06-18","current":-7.69705,"twenty":-19.109305,"median":-12.148707,"eighty":-5.067288,"marketCap":466779913},{"date":"2021-06-25","current":-6.914481,"twenty":-19.109305,"median":-12.059624,"eighty":-5.067288,"marketCap":419321788},{"date":"2021-07-02","current":-6.689358,"twenty":-19.101131,"median":-12.035228,"eighty":-5.067288,"marketCap":405669451},{"date":"2021-07-09","current":-6.507116,"twenty":-19.096054,"median":-12.010832,"eighty":-5.067288,"marketCap":394617559},{"date":"2021-07-16","current":-6.206953,"twenty":-19.021876,"median":-11.953909,"eighty":-5.067288,"marketCap":376414442},{"date":"2021-07-23","current":-5.94967,"twenty":-18.950858,"median":-11.888854,"eighty":-5.067288,"marketCap":360811771},{"date":"2021-07-30","current":-5.799588,"twenty":-18.890929,"median":-11.811434,"eighty":-5.067288,"marketCap":351710213},{"date":"2021-08-06","current":-5.327596,"twenty":-18.810436,"median":-11.750611,"eighty":-5.067288,"marketCap":342074265},{"date":"2021-08-13","current":-4.921684,"twenty":-18.643395,"median":-11.628633,"eighty":-5.057355,"marketCap":316011464},{"date":"2021-08-20","current":-4.728875,"twenty":-18.537367,"median":-11.542992,"eighty":-5.037769,"marketCap":303631633},{"date":"2021-08-27","current":-5.266709,"twenty":-18.470044,"median":-11.449731,"eighty":-5.033251,"marketCap":338164845},{"date":"2021-09-03","current":-5.21597,"twenty":-18.282192,"median":-11.400939,"eighty":-5.033251,"marketCap":334906995},{"date":"2021-09-10","current":-5.195674,"twenty":-18.214367,"median":-11.287092,"eighty":-5.033251,"marketCap":333603855},{"date":"2021-09-17","current":-5.3073,"twenty":-18.011705,"median":-11.171304,"eighty":-5.033251,"marketCap":340771125},{"date":"2021-09-24","current":-5.337744,"twenty":-17.880773,"median":-11.075663,"eighty":-5.033251,"marketCap":342725835},{"date":"2021-10-01","current":-5.185526,"twenty":-17.786094,"median":-11.006109,"eighty":-5.029108,"marketCap":332952285},{"date":"2021-10-08","current":-4.901388,"twenty":-17.593674,"median":-10.888629,"eighty":-5.022352,"marketCap":314708324},{"date":"2021-10-15","current":-5.21597,"twenty":-17.347957,"median":-10.734122,"eighty":-5.022352,"marketCap":334906995},{"date":"2021-10-22","current":-5.418926,"twenty":-17.286901,"median":-10.255278,"eighty":-5.022352,"marketCap":347938396},{"date":"2021-10-29","current":-6.017646,"twenty":-17.190067,"median":-10.091754,"eighty":-5.022352,"marketCap":386381027},{"date":"2021-11-05","current":-5.974365,"twenty":-17.127695,"median":-9.91655,"eighty":-5.022352,"marketCap":430644165},{"date":"2021-11-12","current":-6.354552,"twenty":-17.127695,"median":-9.702195,"eighty":-5.022352,"marketCap":458048794},{"date":"2021-11-19","current":-6.644218,"twenty":-17.127695,"median":-9.581303,"eighty":-5.022352,"marketCap":478928511},{"date":"2021-11-26","current":-6.110146,"twenty":-17.127695,"median":-9.533121,"eighty":-5.022352,"marketCap":440431533},{"date":"2021-12-03","current":-5.983417,"twenty":-17.127695,"median":-9.402102,"eighty":-5.022352,"marketCap":431296656},{"date":"2021-12-10","current":-5.693751,"twenty":-17.127695,"median":-9.370943,"eighty":-5.022352,"marketCap":410416939},{"date":"2021-12-17","current":-5.784271,"twenty":-17.127695,"median":-9.309923,"eighty":-5.022352,"marketCap":416941851},{"date":"2021-12-23","current":-3.819973,"twenty":-17.127695,"median":-9.214034,"eighty":-5.015418,"marketCap":275351269},{"date":"2021-12-31","current":-3.919545,"twenty":-17.127695,"median":-9.097316,"eighty":-4.989045,"marketCap":282528672},{"date":"2022-01-07","current":-3.521254,"twenty":-17.119715,"median":-9.010266,"eighty":-4.966268,"marketCap":253819061},{"date":"2022-01-14","current":-3.575567,"twenty":-17.119715,"median":-8.988637,"eighty":-4.961982,"marketCap":257734008},{"date":"2022-01-21","current":-3.883337,"twenty":-17.119715,"median":-8.85398,"eighty":-4.955638,"marketCap":279918707},{"date":"2022-01-28","current":-3.98291,"twenty":-17.119715,"median":-8.805781,"eighty":-4.940695,"marketCap":287096110},{"date":"2022-02-04","current":-3.856181,"twenty":-17.119715,"median":-8.758021,"eighty":-4.932273,"marketCap":277961234},{"date":"2022-02-11","current":-3.946702,"twenty":-17.119715,"median":-8.737148,"eighty":-4.904186,"marketCap":284486145},{"date":"2022-02-18","current":-3.711348,"twenty":-17.119715,"median":-8.689552,"eighty":-4.87848,"marketCap":267521375},{"date":"2022-02-25","current":-3.647983,"twenty":-17.119715,"median":-8.61807,"eighty":-4.874319,"marketCap":262953937},{"date":"2022-03-04","current":-2.093787,"twenty":-17.061962,"median":-8.407346,"eighty":-4.837766,"marketCap":242607132},{"date":"2022-03-11","current":-2.009133,"twenty":-17.009918,"median":-7.958591,"eighty":-4.791418,"marketCap":232798218},{"date":"2022-03-18","current":-1.811606,"twenty":-16.798456,"median":-7.750651,"eighty":-4.667881,"marketCap":209910753},{"date":"2022-03-25","current":-1.518137,"twenty":-16.708907,"median":-7.65953,"eighty":-4.531833,"marketCap":175906519},{"date":"2022-04-01","current":-1.58586,"twenty":-16.607213,"median":-7.518984,"eighty":-4.457209,"marketCap":183753649},{"date":"2022-04-08","current":-1.50685,"twenty":-16.57374,"median":-7.379808,"eighty":-4.397775,"marketCap":174598663},{"date":"2022-04-14","current":-1.303679,"twenty":-16.518509,"median":-7.230724,"eighty":-4.340581,"marketCap":151057270},{"date":"2022-04-22","current":-1.123083,"twenty":-16.311892,"median":-6.946642,"eighty":-4.261865,"marketCap":130131588},{"date":"2022-04-29","current":-0.965144,"twenty":-16.164988,"median":-6.796842,"eighty":-4.239985,"marketCap":111831187},{"date":"2022-05-06","current":-1.152331,"twenty":-16.037314,"median":-6.714191,"eighty":-4.169443,"marketCap":105945335},{"date":"2022-05-13","current":-1.251915,"twenty":-16.037314,"median":-6.648271,"eighty":-4.143215,"marketCap":115101104},{"date":"2022-05-20","current":-1.152331,"twenty":-16.037314,"median":-6.604751,"eighty":-4.08252,"marketCap":105945335},{"date":"2022-05-27","current":-1.152331,"twenty":-16.037314,"median":-6.566259,"eighty":-4.057616,"marketCap":105945335},{"date":"2022-06-03","current":-1.266142,"twenty":-16.037314,"median":-6.522189,"eighty":-4.032826,"marketCap":116409071},{"date":"2022-06-10","current":-1.323047,"twenty":-16.037314,"median":-6.480379,"eighty":-3.97927,"marketCap":121640940},{"date":"2022-06-17","current":-1.138105,"twenty":-16.037314,"median":-6.433323,"eighty":-3.95309,"marketCap":104637368},{"date":"2022-06-24","current":-1.3515,"twenty":-16.046011,"median":-6.408864,"eighty":-3.934785,"marketCap":124256874},{"date":"2022-07-01","current":-1.308821,"twenty":-16.046011,"median":-6.389195,"eighty":-3.9179,"marketCap":120332973},{"date":"2022-07-08","current":-0.92471,"twenty":-16.046011,"median":-6.376968,"eighty":-3.872475,"marketCap":85017861},{"date":"2022-07-15","current":-1.066973,"twenty":-16.046011,"median":-6.346314,"eighty":-3.809467,"marketCap":98097532},{"date":"2022-07-22","current":-1.031408,"twenty":-16.046011,"median":-6.316646,"eighty":-3.762177,"marketCap":94827614},{"date":"2022-07-29","current":-1.017181,"twenty":-16.046011,"median":-6.308028,"eighty":-3.738504,"marketCap":93519647},{"date":"2022-08-05","current":-1.130019,"twenty":-16.046011,"median":-6.26494,"eighty":-3.711348,"marketCap":109477401},{"date":"2022-08-12","current":-1.136827,"twenty":-16.046011,"median":-6.196,"eighty":-3.671605,"marketCap":110136904},{"date":"2022-08-19","current":-1.130019,"twenty":-16.046011,"median":-6.156937,"eighty":-3.629765,"marketCap":109477401},{"date":"2022-08-26","current":-1.041524,"twenty":-16.046011,"median":-6.121192,"eighty":-3.611561,"marketCap":100903870},{"date":"2022-09-02","current":-0.993872,"twenty":-16.046011,"median":-6.09259,"eighty":-3.569146,"marketCap":96287353},{"date":"2022-09-09","current":-1.089175,"twenty":-16.046011,"median":-6.049502,"eighty":-3.532316,"marketCap":105520387},{"date":"2022-09-16","current":-1.075561,"twenty":-16.046011,"median":-6.027794,"eighty":-3.511462,"marketCap":104201382},{"date":"2022-09-23","current":-0.97345,"twenty":-16.046011,"median":-5.997351,"eighty":-3.486665,"marketCap":94308846},{"date":"2022-09-30","current":-0.987065,"twenty":-16.046011,"median":-5.96096,"eighty":-3.449721,"marketCap":95627850},{"date":"2022-10-07","current":-0.953028,"twenty":-16.046011,"median":-5.928297,"eighty":-3.414806,"marketCap":92330338},{"date":"2022-10-14","current":-0.966643,"twenty":-16.046011,"median":-5.890191,"eighty":-3.396433,"marketCap":93649343},{"date":"2022-10-21","current":-0.905377,"twenty":-16.046011,"median":-5.862972,"eighty":-3.379973,"marketCap":87713821},{"date":"2022-10-28","current":-0.918992,"twenty":-16.046011,"median":-5.831748,"eighty":-3.331334,"marketCap":89032826},{"date":"2022-11-04","current":-0.850918,"twenty":-16.046011,"median":-5.784271,"eighty":-3.323074,"marketCap":82437802},{"date":"2022-11-11","current":-0.873514,"twenty":-16.046011,"median":-5.732321,"eighty":-3.273141,"marketCap":85248833},{"date":"2022-11-18","current":-1.178228,"twenty":-16.046011,"median":-5.677883,"eighty":-3.251622,"marketCap":114986798},{"date":"2022-11-25","current":-1.225628,"twenty":-16.046011,"median":-5.650664,"eighty":-3.224416,"marketCap":119612704},{"date":"2022-12-02","current":-1.157914,"twenty":-16.046011,"median":-5.620336,"eighty":-3.195939,"marketCap":113004267},{"date":"2022-12-09","current":-1.049571,"twenty":-16.046011,"median":-5.607113,"eighty":-3.110828,"marketCap":102430768},{"date":"2022-12-16","current":-1.063114,"twenty":-16.046011,"median":-5.569007,"eighty":-2.986764,"marketCap":103752456},{"date":"2022-12-23","current":-1.049571,"twenty":-16.046011,"median":-5.5407,"eighty":-2.919362,"marketCap":102430768},{"date":"2022-12-30","current":-1.083428,"twenty":-16.046011,"median":-5.520013,"eighty":-2.905032,"marketCap":105734987},{"date":"2023-01-06","current":-1.706399,"twenty":-16.021613,"median":-5.479813,"eighty":-2.876488,"marketCap":166532604},{"date":"2023-01-13","current":-1.936628,"twenty":-15.815007,"median":-5.458069,"eighty":-2.826882,"marketCap":189001289},{"date":"2023-01-20","current":-1.706399,"twenty":-15.672234,"median":-5.418926,"eighty":-2.80972,"marketCap":166532604},{"date":"2023-01-27","current":-1.875685,"twenty":-15.467441,"median":-5.400249,"eighty":-2.756449,"marketCap":183053696},{"date":"2023-02-03","current":-1.794428,"twenty":-15.286312,"median":-5.341948,"eighty":-2.654972,"marketCap":175123572},{"date":"2023-02-10","current":-1.719942,"twenty":-14.767548,"median":-5.325305,"eighty":-2.465003,"marketCap":167854292},{"date":"2023-02-17","current":-1.598056,"twenty":-14.638832,"median":-5.295802,"eighty":-2.294544,"marketCap":155959106},{"date":"2023-02-24","current":-1.442313,"twenty":-14.517074,"median":-5.28105,"eighty":-2.219541,"marketCap":140759701},{"date":"2023-03-03","current":-1.449085,"twenty":-14.054392,"median":-5.266709,"eighty":-2.138936,"marketCap":141420545},{"date":"2023-03-10","current":-1.259485,"twenty":-13.803918,"median":-5.257251,"eighty":-2.004618,"marketCap":122916922},{"date":"2023-03-17","current":-1.259485,"twenty":-13.049016,"median":-5.222044,"eighty":-1.906833,"marketCap":122916922},{"date":"2023-03-24","current":-1.151142,"twenty":-12.765494,"median":-5.214668,"eighty":-1.859433,"marketCap":112343423},{"date":"2023-03-31","current":-1.006921,"twenty":-12.62808,"median":-5.195674,"eighty":-1.814742,"marketCap":100004349},{"date":"2023-04-06","current":-0.993584,"twenty":-12.403697,"median":-5.18509,"eighty":-1.790365,"marketCap":98679788},{"date":"2023-04-14","current":-1.153624,"twenty":-12.106258,"median":-5.17779,"eighty":-1.734306,"marketCap":114574519},{"date":"2023-04-21","current":-1.086941,"twenty":-11.986239,"median":-5.165231,"eighty":-1.693089,"marketCap":107951714},{"date":"2023-04-28","current":-1.062043,"twenty":-11.596613,"median":-5.154405,"eighty":-1.669474,"marketCap":105478911},{"date":"2023-05-05","current":-1.115479,"twenty":-11.092,"median":-5.126159,"eighty":-1.604589,"marketCap":110786026},{"date":"2023-05-12","current":-1.662065,"twenty":-10.241261,"median":-5.114492,"eighty":-1.592633,"marketCap":117419920},{"date":"2023-05-18","current":-1.662065,"twenty":-10.005621,"median":-5.08928,"eighty":-1.592633,"marketCap":117419920},{"date":"2023-05-26","current":-1.605724,"twenty":-9.707425,"median":-5.066683,"eighty":-1.590375,"marketCap":113439583},{"date":"2023-06-02","current":-1.577553,"twenty":-9.509003,"median":-5.05675,"eighty":-1.577553,"marketCap":111449415},{"date":"2023-06-07","current":-1.586944,"twenty":-9.43545,"median":-5.053605,"eighty":-1.577553,"marketCap":112112805},{"date":"2023-06-16","current":-1.464871,"twenty":-9.370943,"median":-5.035235,"eighty":-1.563286,"marketCap":103488743},{"date":"2023-06-23","current":-1.42731,"twenty":-9.282028,"median":-5.023162,"eighty":-1.535759,"marketCap":100835185},{"date":"2023-06-30","current":-1.324018,"twenty":-9.164912,"median":-5.015391,"eighty":-1.507486,"marketCap":93537902},{"date":"2023-07-07","current":-1.699626,"twenty":-9.072816,"median":-4.992228,"eighty":-1.507486,"marketCap":120073477},{"date":"2023-07-14","current":-1.699626,"twenty":-8.996105,"median":-4.978644,"eighty":-1.50685,"marketCap":120073477},{"date":"2023-07-21","current":-1.680846,"twenty":-8.922199,"median":-4.962275,"eighty":-1.50685,"marketCap":118746699},{"date":"2023-07-28","current":-1.605724,"twenty":-8.822663,"median":-4.956516,"eighty":-1.50685,"marketCap":113439583},{"date":"2023-08-04","current":-1.577553,"twenty":-8.779783,"median":-4.941765,"eighty":-1.50685,"marketCap":111449415},{"date":"2023-08-11","current":-2.38569,"twenty":-8.747969,"median":-4.933588,"eighty":-1.50685,"marketCap":113439583},{"date":"2023-08-18","current":-2.35532,"twenty":-8.735869,"median":-4.904886,"eighty":-1.50685,"marketCap":99483990},{"date":"2023-08-25","current":-2.339512,"twenty":-8.649934,"median":-4.879071,"eighty":-1.50685,"marketCap":98816312},{"date":"2023-09-01","current":-2.371127,"twenty":-8.539552,"median":-4.870065,"eighty":-1.50685,"marketCap":100151668},{"date":"2023-09-08","current":-2.181437,"twenty":-8.281298,"median":-4.838504,"eighty":-1.50685,"marketCap":92139535},{"date":"2023-09-15","current":-2.181437,"twenty":-7.808558,"median":-4.797468,"eighty":-1.50685,"marketCap":92139535},{"date":"2023-09-22","current":-2.118207,"twenty":-7.690618,"median":-4.694622,"eighty":-1.50685,"marketCap":89468823},{"date":"2023-09-29","current":-2.023362,"twenty":-7.570553,"median":-4.543378,"eighty":-1.50685,"marketCap":85462757},{"date":"2023-10-06","current":-1.944324,"twenty":-7.460249,"median":-4.47683,"eighty":-1.50685,"marketCap":82124368},{"date":"2023-10-13","current":-1.896902,"twenty":-7.296875,"median":-4.400739,"eighty":-1.50685,"marketCap":80121334},{"date":"2023-10-20","current":-2.118207,"twenty":-7.080972,"median":-4.345558,"eighty":-1.50685,"marketCap":89468823},{"date":"2023-10-27","current":-1.786249,"twenty":-6.897329,"median":-4.267384,"eighty":-1.50685,"marketCap":75447590},{"date":"2023-11-03","current":-1.849479,"twenty":-6.768204,"median":-4.253588,"eighty":-1.50685,"marketCap":78118301},{"date":"2023-11-10","current":-5.023281,"twenty":-6.674971,"median":-4.240889,"eighty":-1.50685,"marketCap":80121334},{"date":"2023-11-17","current":-8.487937,"twenty":-6.669198,"median":-4.240889,"eighty":-1.50685,"marketCap":86415686},{"date":"2023-11-24","current":-8.948523,"twenty":-6.669198,"median":-4.240889,"eighty":-1.50685,"marketCap":91104909},{"date":"2023-12-01","current":-9.145917,"twenty":-6.669198,"median":-4.240889,"eighty":-1.50685,"marketCap":93114576},{"date":"2023-12-08","current":-9.606502,"twenty":-6.671374,"median":-4.24264,"eighty":-1.50685,"marketCap":97803799},{"date":"2023-12-15","current":-9.6723,"twenty":-6.669198,"median":-4.240889,"eighty":-1.50685,"marketCap":98473688},{"date":"2023-12-22","current":-9.277512,"twenty":-6.669198,"median":-4.240889,"eighty":-1.50685,"marketCap":94454354},{"date":"2023-12-29","current":-10.165785,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":103497856},{"date":"2024-01-05","current":-10.198684,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":103832801},{"date":"2024-01-12","current":-11.119855,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":113211247},{"date":"2024-01-19","current":-11.054057,"twenty":-6.64075,"median":-4.231182,"eighty":-1.50685,"marketCap":112541358},{"date":"2024-01-26","current":-10.067088,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":102493023},{"date":"2024-02-02","current":-10.067088,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":102493023},{"date":"2024-02-09","current":-9.606502,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":97803799},{"date":"2024-02-16","current":-9.869694,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":100483356},{"date":"2024-02-23","current":-9.738098,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":99143577},{"date":"2024-03-01","current":-16.1205,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":164122814},{"date":"2024-03-08","current":-16.844278,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":171491594},{"date":"2024-03-15","current":-245.178585,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":139506615},{"date":"2024-03-22","current":-266.601956,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":151696513},{"date":"2024-03-28","current":-260.689917,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":148332563},{"date":"2024-04-05","current":-245.215172,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":139527433},{"date":"2024-04-12","current":-255.928457,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":145623292},{"date":"2024-04-19","current":-205.93313,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":117175951},{"date":"2024-04-26","current":-190.458387,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":108370822},{"date":"2024-05-03","current":-535.664214,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":304792938},{"date":"2024-05-10","current":8.357394,"twenty":-6.64746,"median":-4.217605,"eighty":-1.472316,"marketCap":138172798},{"date":"2024-05-17","current":8.193524,"twenty":-6.64746,"median":-4.155757,"eighty":-1.455856,"marketCap":135463528},{"date":"2024-05-24","current":8.624717,"twenty":-6.64746,"median":-4.086161,"eighty":-1.44458,"marketCap":142592445},{"date":"2024-05-31","current":8.24768,"twenty":-6.64746,"median":-4.078366,"eighty":-1.425186,"marketCap":136358895},{"date":"2024-06-07","current":7.870643,"twenty":-6.64746,"median":-4.044422,"eighty":-1.381595,"marketCap":130125346},{"date":"2024-06-14","current":6.880922,"twenty":-6.649081,"median":-4.02817,"eighty":-1.363555,"marketCap":113762278},{"date":"2024-06-21","current":6.032589,"twenty":-6.650702,"median":-3.970254,"eighty":-1.332765,"marketCap":99736792},{"date":"2024-06-28","current":5.93833,"twenty":-6.658855,"median":-3.954687,"eighty":-1.325927,"marketCap":98178404},{"date":"2024-07-05","current":6.126848,"twenty":-6.658855,"median":-3.93891,"eighty":-1.323047,"marketCap":101295179},{"date":"2024-07-12","current":6.598144,"twenty":-6.653992,"median":-3.9179,"eighty":-1.302891,"marketCap":109087116},{"date":"2024-07-15","current":6.692403,"twenty":-6.653992,"median":-3.9179,"eighty":-1.298362,"marketCap":110645503},{"date":"2024-08-02","current":6.315366,"twenty":-6.689358,"median":-3.816355,"eighty":-1.266142,"marketCap":104411954},{"date":"2024-08-09","current":8.314881,"twenty":-6.689358,"median":-3.774712,"eighty":-1.247243,"marketCap":92178769},{"date":"2024-08-16","current":8.385346,"twenty":-6.689358,"median":-3.738504,"eighty":-1.230576,"marketCap":92959945},{"date":"2024-08-23","current":8.385346,"twenty":-6.689358,"median":-3.711348,"eighty":-1.212085,"marketCap":92959945},{"date":"2024-08-30","current":8.103486,"twenty":-6.689358,"median":-3.684192,"eighty":-1.202123,"marketCap":89835241},{"date":"2024-09-06","current":8.314881,"twenty":-6.689358,"median":-3.65026,"eighty":-1.178228,"marketCap":92178769},{"date":"2024-09-13","current":8.808136,"twenty":-6.689358,"median":-3.616096,"eighty":-1.164056,"marketCap":97647001},{"date":"2024-09-20","current":8.244416,"twenty":-6.689358,"median":-3.581932,"eighty":-1.153624,"marketCap":91397593},{"date":"2024-09-27","current":8.455811,"twenty":-6.689358,"median":-3.549144,"eighty":-1.151142,"marketCap":93741121},{"date":"2024-10-04","current":7.962555,"twenty":-6.689358,"median":-3.547642,"eighty":-1.145218,"marketCap":88272889},{"date":"2024-10-11","current":7.89209,"twenty":-6.689358,"median":-3.547642,"eighty":-1.138105,"marketCap":87491713},{"date":"2024-10-18","current":8.173951,"twenty":-6.689358,"median":-3.547642,"eighty":-1.133619,"marketCap":90616417},{"date":"2024-10-25","current":7.61023,"twenty":-6.689358,"median":-3.547642,"eighty":-1.123879,"marketCap":84367009},{"date":"2024-10-31","current":6.990137,"twenty":-6.689358,"median":-3.547642,"eighty":-1.123212,"marketCap":77492660},{"date":"2024-11-08","current":5.648417,"twenty":-6.689382,"median":-3.557463,"eighty":-1.116693,"marketCap":78117601},{"date":"2024-11-15","current":5.658632,"twenty":-6.689382,"median":-3.557463,"eighty":-1.109597,"marketCap":78258879},{"date":"2024-11-22","current":4.903204,"twenty":-6.689382,"median":-3.557463,"eighty":-1.103501,"marketCap":67811318},{"date":"2024-11-29","current":5.99815,"twenty":-6.689382,"median":-3.557463,"eighty":-1.100278,"marketCap":82954411},{"date":"2024-12-06","current":6.564013,"twenty":-6.689382,"median":-3.557463,"eighty":-1.089994,"marketCap":90780299},{"date":"2024-12-13","current":6.337668,"twenty":-6.689382,"median":-3.557463,"eighty":-1.088313,"marketCap":87649944},{"date":"2024-12-20","current":6.224495,"twenty":-6.689382,"median":-3.524056,"eighty":-1.083428,"marketCap":86084766},{"date":"2024-12-27","current":6.394254,"twenty":-6.689382,"median":-3.50315,"eighty":-1.075266,"marketCap":88432533},{"date":"2025-01-03","current":5.99815,"twenty":-6.689382,"median":-3.466942,"eighty":-1.066973,"marketCap":82954411},{"date":"2025-01-10","current":5.561303,"twenty":-6.689406,"median":-3.432284,"eighty":-1.062686,"marketCap":76912826},{"date":"2025-01-17","current":4.793427,"twenty":-6.689406,"median":-3.407046,"eighty":-1.052912,"marketCap":66293096},{"date":"2025-01-24","current":4.910561,"twenty":-6.689406,"median":-3.383641,"eighty":-1.045009,"marketCap":67913055},{"date":"2025-01-31","current":4.951303,"twenty":-6.689406,"median":-3.339237,"eighty":-1.04102,"marketCap":68476519},{"date":"2025-02-07","current":4.92301,"twenty":-6.689406,"median":-3.312429,"eighty":-1.030008,"marketCap":68085224},{"date":"2025-02-14","current":4.675727,"twenty":-6.689406,"median":-3.262613,"eighty":-1.023149,"marketCap":64665311},{"date":"2025-02-21","current":4.618009,"twenty":-6.689406,"median":-3.171091,"eighty":-1.017181,"marketCap":63867071},{"date":"2025-02-28","current":3.820708,"twenty":-6.689406,"median":-2.946017,"eighty":-1.014294,"marketCap":52840395},{"date":"2025-03-07","current":3.493073,"twenty":-6.68943,"median":-2.758827,"eighty":-1.008519,"marketCap":48309206},{"date":"2025-03-14","current":1.484923,"twenty":-6.68943,"median":-2.592432,"eighty":-0.997777,"marketCap":47323014},{"date":"2025-03-21","current":1.67368,"twenty":-6.68943,"median":-2.592432,"eighty":-0.993872,"marketCap":53338516},{"date":"2025-03-28","current":1.549769,"twenty":-6.68943,"median":-2.38569,"eighty":-0.983881,"marketCap":49389591},{"date":"2025-04-04","current":1.365033,"twenty":-6.68943,"median":-2.35532,"eighty":-0.968301,"marketCap":43502249},{"date":"2025-04-11","current":1.243133,"twenty":-6.689406,"median":-2.315801,"eighty":-0.959836,"marketCap":39617405},{"date":"2025-04-17","current":1.582695,"twenty":-6.689406,"median":-2.277053,"eighty":-0.953028,"marketCap":50438900},{"date":"2025-04-25","current":1.92477,"twenty":-6.68943,"median":-2.181437,"eighty":-0.913887,"marketCap":61340494},{"date":"2025-05-02","current":1.903406,"twenty":-6.68943,"median":-2.155867,"eighty":-0.89857,"marketCap":60659645},{"date":"2025-05-09","current":2.757451,"twenty":-6.660512,"median":-2.134014,"eighty":-0.878933,"marketCap":87877209},{"date":"2025-05-16","current":7.573702,"twenty":-6.623429,"median":-2.093787,"eighty":-0.851831,"marketCap":315088738},{"date":"2025-05-23","current":8.065993,"twenty":-6.623429,"median":-2.009133,"eighty":-0.824759,"marketCap":335569505},{"date":"2025-05-30","current":9.542865,"twenty":-6.623429,"median":-1.991747,"eighty":1.144607,"marketCap":397011809},{"date":"2025-06-06","current":9.088443,"twenty":-6.623429,"median":-1.975939,"eighty":1.42068,"marketCap":378106485},{"date":"2025-06-09","current":9.997287,"twenty":-6.623429,"median":-1.975939,"eighty":1.474065,"marketCap":415917134}],"updateTime":1749549603499}}}